Search Bar & Filters
Found 43 Actively Recruiting clinical trials
Actively Recruiting
Researchers are investigating new treatments for metastatic castration-resistant prostate cancer mCRPC. This study evaluates the medicine ifinatamab deruxtecan I-DXd or MK-2400 compared to chemotherapy to see if it helps people live longer overall and without cancer progression. The trial is sponsored by Merck Sharp & Dohme LLC and focuses on men with advanced prostate cancer who have tried other therapies. Participants are randomly assigned to one of two groups. One group receives I-DXd at 12 mg per kg every three weeks through intravenous infusion, along with premedication to prevent nausea and vomiting. The other group receives docetaxel chemotherapy at 75 mgm every three weeks plus daily oral prednisone. Treatments continue until the cancer worsens, side effects are unacceptable, or treatment stops for other reasons. During the study, participants will have regular assessments to monitor overall survival and how long they live without cancer progression, up to about 36 months. Researchers will also track additional outcomes like time to subsequent therapies, response rates, pain progression, and side effects. Safety and treatment tolerability will be closely monitored throughout the trial, which may last up to six years for some participants.
Actively Recruiting
Researchers are evaluating Dostarlimab compared to a placebo in adults with locally advanced unresected Head and Neck Squamous Cell Carcinoma HNSCC. This phase 3 trial aims to assess the safety and effectiveness of Dostarlimab as a sequential therapy following chemoradiation treatment in participants with this type of cancer. Participants are randomly assigned to receive either Dostarlimab or a placebo, both given as intravenous infusions. The study is double-blind, meaning neither the participants nor the researchers know which treatment is being given. The treatments follow completion of chemoradiation with cisplatin and radiotherapy intended to cure the cancer. During the study, participants will be monitored for up to approximately 5 years. Researchers will evaluate event-free survival and overall survival, with safety assessments including treatment-emergent adverse events and laboratory tests. Blood samples will be taken to measure drug levels and immune responses. This long-term follow-up will help understand the effects and safety of Dostarlimab after chemoradiation therapy.
Actively Recruiting
Researchers are evaluating whether adding sacituzumab tirumotecan to pembrolizumab after surgery improves treatment outcomes for adults with resectable non-small cell lung cancer NSCLC who did not achieve a complete response after initial therapy. The study focuses on comparing disease-free survival between participants receiving pembrolizumab alone and those receiving a combination of pembrolizumab and sacituzumab tirumotecan. The trial is a phase 3, randomized, open-label study sponsored by Merck Sharp & Dohme LLC. Participants first receive pembrolizumab combined with platinum-based doublet chemotherapy as neoadjuvant therapy before surgery. After surgery, participants who did not achieve pathological complete response are assigned to one of two groups one group receives sacituzumab tirumotecan every two weeks for up to 12 doses alongside pembrolizumab every six weeks for up to seven cycles, while the other group receives pembrolizumab monotherapy every six weeks for up to seven cycles. The neoadjuvant chemotherapy includes drugs such as cisplatin, pemetrexed, gemcitabine, carboplatin, and paclitaxel, chosen based on tumor histology. Throughout the study, participants will be monitored regularly with assessments including imaging scans to evaluate disease status and quality of life questionnaires. The primary outcome is disease-free survival assessed by blinded independent central review for up to approximately 93 months. Secondary outcomes include overall survival, lung cancer-specific survival, adverse events, and changes in physical functioning and symptoms related to lung cancer. The study duration can last up to nearly 10 years with follow-up visits to monitor health and treatment effects.
Actively Recruiting
Researchers are conducting an international, multicenter, open-label phase III trial to evaluate the addition of adjuvant durvalumab after neoadjuvant chemotherapy combined with durvalumab and surgery in patients with early-stage, operable non-small cell lung cancer NSCLC stages IIB to IIIB. The main goal is to see if giving durvalumab after surgery improves disease-free survival in patients who do not achieve complete pathological response after initial treatment. The treatment plan involves 3 to 4 cycles of neoadjuvant durvalumab combined with platinum-based doublet chemotherapy, followed by surgery to remove the tumor. After surgery, patients with complete R0 or microscopic residual R1 resection are randomly assigned to either receive adjuvant durvalumab given intravenously at 1500 mg every 4 weeks for up to 12 cycles or to be observed without additional treatment. Participants will be monitored regularly for about 60 months after randomization to assess disease-free survival and other outcomes such as overall survival, time to recurrence, and treatment toxicity. Assessments include imaging scans to check for metastatic disease, pathological review after surgery, and ongoing safety evaluations. Participants must attend scheduled visits and follow study procedures throughout the treatment and follow-up periods.
Actively Recruiting
Researchers are evaluating treatments for people with advanced non-small cell lung cancer NSCLC that has spread or cannot be controlled by current therapies. This study focuses on patients whose cancer cells have specific changes called HER2 mutations, which cause abnormal cell growth. The main goal is to compare the effectiveness and safety of a new drug called sevabertinib against the standard treatment for this condition. Participants will be randomly assigned to one of two groups one group will take sevabertinib tablets twice daily, and the other will receive the current standard treatment, which includes pembrolizumab combined with platinum-based chemotherapy given by vein infusion every 21 days. Those on standard treatment may switch to sevabertinib if their cancer worsens. Treatment continues as long as participants benefit and do not have severe side effects. During the study, participants will undergo scans like CT, PET, MRI, or X-rays to monitor their cancer. Health assessments include blood and urine tests, heart checks using electrocardiograms and echocardiograms, pregnancy tests when needed, and evaluations of how participants feel and any medical problems they experience. The main outcome measured is how long participants live without their cancer progressing, with other outcomes including overall survival and response rates. The study lasts up to about 4 years, with ongoing monitoring for safety and patient well-being.
Actively Recruiting
Researchers are evaluating whether antibiotic treatment is necessary for children with community-acquired pneumonia caused by the bacterium Mycoplasma pneumoniae. This trial compares the effects of a commonly used antibiotic, azithromycin, with a placebo in children aged 3 to 17 years. The study addresses concerns about increasing antibiotic resistance and aims to improve treatment decisions for this common cause of pneumonia in children. Participants are randomly assigned to receive either azithromycin or a placebo for five days. The azithromycin group takes a daily dose of 10mgkg on the first day followed by 5mgkg on days 2 through 5. This randomized, double-blind, placebo-controlled trial takes place across multiple pediatric centers and includes both ambulatory and hospitalized children. The study involves initial screening to confirm Mycoplasma pneumoniae infection using a specific antibody test before starting the assigned treatment. During the study, researchers will monitor symptom duration, vital signs, and changes in patient care status for up to 28 days. They will also assess overall clinical outcomes, symptom resolution, quality of life impacts on the family, time to return to normal daily activities, and the development of any complications related to the infection. Follow-up includes clinical examinations and parent reports to track progress and safety throughout the study period.
Actively Recruiting
Researchers are evaluating the clinical effectiveness of tarlatamab in patients with extensive-stage small cell lung cancer ES-SCLC who have an ECOG Performance Status of 2 and have previously received only one line of platinum-etoposide chemotherapy combined with immune-checkpoint inhibition. This international, multicenter Phase II trial aims to measure the 12-month overall survival rate in this patient group whose disease has progressed. The study focuses on treatment options for patients with this advanced lung cancer subtype and limited prior therapy. Participants receive tarlatamab through an intravenous infusion starting with 1 mg on day 1, followed by 10 mg on days 8 and 15 of the first cycle, then 10 mg every two weeks thereafter. Treatment continues until disease progression according to RECIST v1.1 criteria, unacceptable side effects, or patient choice. This single-arm trial monitors patients receiving this drug regimen to assess its effects over time. During the study, participants will be closely monitored for overall survival, objective response rate, duration of response, disease control rate, progression-free survival, and the incidence and severity of any adverse events. These outcomes will be assessed for up to approximately 41 months from enrollment. Patients will undergo regular evaluations including clinical assessments and safety monitoring throughout their participation, which may last until disease progression or other study endpoints.
Actively Recruiting
Researchers are evaluating the addition of bleximenib, a drug that blocks a specific protein interaction in leukemia cells, to standard chemotherapy for adults with newly diagnosed acute myeloid leukemia AML who have mutations in the NPM1 or KMT2A genes. This phase 3, randomized, double-blind, placebo-controlled trial aims to see if bleximenib improves treatment outcomes compared to chemotherapy alone. Participants will be randomly assigned to one of three groups standard chemotherapy plus bleximenib with bleximenib maintenance, standard chemotherapy plus bleximenib with placebo maintenance, or standard chemotherapy plus placebo with placebo maintenance. Treatment continues until disease progression, unacceptable side effects, or other criteria require stopping. After the treatment phase, all participants will be followed observationally for up to four years to compare long-term outcomes. During the study, participants will receive standard chemotherapy drugs including cytarabine and daunorubicin or idarubicin, alongside the study drug or placebo. Researchers will monitor event-free survival as the primary outcome over up to four years and five months. Secondary outcomes include overall survival, remission rates, duration of remission, and the percentage undergoing stem cell transplantation, with follow-up extending up to nearly eight years. Safety and treatment effects will be closely observed throughout the study period.
Actively Recruiting
Researchers are studying hereditary breast and ovarian cancer HBOC and Lynch syndrome LS, which together account for about 30% of new cancer cases in Switzerland. The study focuses on genetic testing for these hereditary cancers to identify mutation carriers and improve prevention through early detection and management. Despite available genetic services, many mutation carriers and their family members do not use these services due to care coordination and communication challenges. The study uses a family-based cohort approach called CASCADE genetic screening, involving mutation carriers, their blood relatives who test negative, and untested relatives. It aims to survey index patients with HBOC or LS and their family members to understand their cancer status, genetic testing use, care coordination needs, communication patterns, and quality of life. The study will also explore the acceptability of a family-based communication and decision support intervention. Participants will be involved in surveys assessing their cancer and genetic mutation status, surveillance practices, psychosocial needs, communication with providers and family, and willingness to engage in genetic services. The primary outcome is establishing the CASCADE cohort within 12 months, with secondary outcomes including cancer surveillance practices. The study is observational and ongoing, with participants living in Switzerland and able to communicate in German, French, Italian, or English.
Actively Recruiting
Researchers are investigating the best approach to treat low-risk patients with isolated subsegmental pulmonary embolism SSPE, a type of blood clot in small lung arteries. The study aims to determine whether monitoring patients without anticoagulation is as safe and effective as giving anticoagulant medication. This is important because many patients currently receive anticoagulants that carry a risk of bleeding, but it is unclear if all patients with isolated SSPE need this treatment. Patients in the trial are randomly assigned to one of two groups. One group receives the anticoagulant drug rivaroxaban, starting with 15 mg twice daily for 21 days, then 20 mg once daily for a total of 90 days. The other group receives a placebo matching the same schedule. The trial compares clinical surveillance without anticoagulation to anticoagulation treatment to assess safety and effectiveness. Participants will be followed for 90 days after randomization to monitor for recurrent venous thromboembolism, significant bleeding events, and overall survival. Researchers will track these outcomes through clinical assessments and safety monitoring. This study is designed to evaluate if careful monitoring alone is a safe alternative to anticoagulation in selected patients with isolated SSPE, potentially reducing bleeding risks from treatment.
1-10 of 43
1